Diabetes group challenges FDA decision on drug warnings

01/29/2004 | Forbes

The American Diabetes Association, backed by several other medical groups, sponsored an opinion paper concluding some anti-psychotic medicines carry more diabetes risk than others and the FDA's decision to apply the same warning to all such medicines should be changed. Eli Lilly, maker of Zyprexa, a schizophrenia drug, said it does not agree with the conclusions of the paper, which also warned the inconsistency in warnings could confuse doctors and patients.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC